Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

Sandra Villagómez‐Martínez; Susanna M. Kharit; A.N. Galustyan; Betzana Zambrano; Mandeep Singh Dhingra; Siham B’Chir; Olga Syrkina; Olga Lyabis; Christine Rehm

doi:10.6084/m9.figshare.30999678

Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study

Figshare 2026 Open access

Read full text

Authors: Sandra Villagómez‐Martínez, Susanna M. Kharit, A.N. Galustyan, Betzana Zambrano, Mandeep Singh Dhingra, Siham B’Chir, Olga Syrkina, Olga Lyabis, Christine Rehm

DOI: 10.6084/m9.figshare.30999678

Cited by: 0

Abstract

MenACYW-TT (MenQuadfi®), a quadrivalent meningococcal conjugate vaccine, is approved for use in individuals aged ≥12 months or ≥6 weeks depending on the country. This study reported the immunogenicity and safety of MenACYW-TT in individuals aged

Fields of Study & Subjects

Bacterial Infections and Vaccines Herpesvirus Infections and Treatments Virology and Viral Diseases

Publication details

Journal / source: Figshare
Publication date: 5 January 2026